dc.contributor.author |
Mansilla Lopez, Maria Jose |
dc.contributor.author |
Contreras-Cardone, Raian |
dc.contributor.author |
Navarro-Barriuso, Juan |
dc.contributor.author |
Cools, Nathalie |
dc.contributor.author |
Berneman, Zwi |
dc.contributor.author |
Ramo-Tello, Cristina |
dc.contributor.author |
Martínez Cáceres, Eva María |
dc.contributor.author |
Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia |
dc.date |
2016 |
dc.identifier |
https://ddd.uab.cat/record/174658 |
dc.identifier |
urn:10.1186/s12974-016-0584-9 |
dc.identifier |
urn:oai:ddd.uab.cat:174658 |
dc.identifier |
urn:pmid:27207486 |
dc.identifier |
urn:scopus_id:84974575595 |
dc.identifier |
urn:wos_id:000377285900001 |
dc.identifier |
urn:altmetric_id:8111112 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/fd231a59-a04f-46b2-8ecc-a81bd23ae652 |
dc.identifier |
urn:pmc-uid:4874005 |
dc.identifier |
urn:pmcid:PMC4874005 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:4874005 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Ministerio de Economía y Competitividad ISCIII/PI11/02416 |
dc.relation |
Journal of neuroinflammation ; Vol. 13, No. 113 (May 2016) |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Breg |
dc.subject |
EAE |
dc.subject |
Multiple sclerosis |
dc.subject |
NK cells |
dc.subject |
NKT cells |
dc.subject |
Tolerogenic dendritic cells |
dc.subject |
Treg |
dc.title |
Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients |
dc.type |
Article |
dc.description.abstract |
Altres ajuts: Cost Action BM1305 |
dc.description.abstract |
BACKGROUND: Tolerogenic dendritic cells (tolDC) have been postulated as a potent immunoregulatory therapy for autoimmune diseases such as multiple sclerosis (MS). In a previous study, we demonstrated that the administration of antigen-specific vitamin D3 (vitD3) tolDC in mice showing clinical signs of experimental autoimmune encephalomyelitis (EAE; the animal model of MS) resulted in abrogation of disease progression. With the purpose to translate this beneficial therapy to the clinics, we have investigated the effectivity of vitD3-frozen antigen-specific tolDC pulsed with myelin oligodendrocyte glycoprotein 40-55 peptide (f-tolDC-MOG) since it would reduce the cost, functional variability and number of leukapheresis to perform to the patients. METHODS: Mice showing EAE clinical signs were treated with repetitive doses of f-tolDC-MOG. Tolerogenic mechanisms induced by the therapy were analysed by flow cytometry and T cell proliferation assays. RESULTS: Treatment with f-tolDC-MOG was effective in ameliorating clinical signs of mice with EAE, inhibiting antigen-specific reactivity and inducing Treg. In addition, the long-term treatment was well tolerated and leading to a prolonged maintenance of tolerogenicity mediated by induction of Breg, reduction of NK cells and activation of immunoregulatory NKT cells. CONCLUSIONS: The outcomes of this study show that the use of antigen-specific f-tolDC promotes multiple and potent tolerogenic mechanisms. Moreover, these cells can be kept frozen maintaining their tolerogenic properties, which is a relevant step for their translation to the clinic. Altogether, vitD3 f-tolDC-MOG is a potential strategy to arrest the autoimmune destruction in MS patients. |